AbstractAutosomal recessive osteopetrosis (OP) is a rare, lethal disorder in which osteoclasts are absent or nonfunctional, resulting in a bone marrow cavity insufficient to support hematopoiesis. Because osteoclasts are derived from hematopoietic precursors, allogeneic hematopoietic cell transplantation can cure the bony manifestations of the disorder. However, high rates of graft failure have been observed in this population. It is not possible to harvest bone marrow from these patients for reinfusion should graft failure be observed. We report that 8 of 10 patients with OP had high numbers of circulating CD34+ cells (3% ± 0.9%). This increased proportion of peripheral CD34+ cells made it possible to harvest 2 × 106 CD34+ cells per kilogr...
Background: Osteopetrosis is a rare hereditary bone dysplasia characterized by insufficient osteocla...
Lack of or dysfunction in osteoclasts result in osteopetrosis, a group of rare but often severe, gen...
Bone biopsies were performed before and 7 weeks after transplantation of HLA-compatible bone marrow ...
AbstractAutosomal recessive osteopetrosis (OP) is a rare, lethal disorder in which osteoclasts are a...
Allogeneic hematopoietic stem cell transplantation is the treatment of choice for autosomal recessiv...
In osteopetrosis, osteoclast dysfunction can lead to deafness, blindness, bone marrow failure, and d...
Infantile malignant osteopetrosis (IMO) is caused by lack of functional osteoclasts leading to skele...
Infantile malignant osteopetrosis (IMO) is caused by lack of functional osteoclasts leading to skele...
This thesis focuses on developing stem cell targeted gene therapy for the severe hereditary disorder...
Malignant autosomal recessive (AR) osteopetrosis represents an absolute indication for bone marrow t...
Autosomal recessive osteopetrosis (ARO) is a severe inherited bone disease characterized by defectiv...
Hematopoietic stem cell transplantation (HSCT) is often the only practical approach to fatal genetic...
Autosomal recessive osteopetrosis is a human bone disease mainly caused by TCIRG1 gene mutations tha...
BACKGROUND: Infantile malignant osteopetrosis (IMO) is an autosomal recessive disorder characterized...
Infantile malignant osteopetrosis (IMO) is a rare, lethal, autosomal recessive disorder characterize...
Background: Osteopetrosis is a rare hereditary bone dysplasia characterized by insufficient osteocla...
Lack of or dysfunction in osteoclasts result in osteopetrosis, a group of rare but often severe, gen...
Bone biopsies were performed before and 7 weeks after transplantation of HLA-compatible bone marrow ...
AbstractAutosomal recessive osteopetrosis (OP) is a rare, lethal disorder in which osteoclasts are a...
Allogeneic hematopoietic stem cell transplantation is the treatment of choice for autosomal recessiv...
In osteopetrosis, osteoclast dysfunction can lead to deafness, blindness, bone marrow failure, and d...
Infantile malignant osteopetrosis (IMO) is caused by lack of functional osteoclasts leading to skele...
Infantile malignant osteopetrosis (IMO) is caused by lack of functional osteoclasts leading to skele...
This thesis focuses on developing stem cell targeted gene therapy for the severe hereditary disorder...
Malignant autosomal recessive (AR) osteopetrosis represents an absolute indication for bone marrow t...
Autosomal recessive osteopetrosis (ARO) is a severe inherited bone disease characterized by defectiv...
Hematopoietic stem cell transplantation (HSCT) is often the only practical approach to fatal genetic...
Autosomal recessive osteopetrosis is a human bone disease mainly caused by TCIRG1 gene mutations tha...
BACKGROUND: Infantile malignant osteopetrosis (IMO) is an autosomal recessive disorder characterized...
Infantile malignant osteopetrosis (IMO) is a rare, lethal, autosomal recessive disorder characterize...
Background: Osteopetrosis is a rare hereditary bone dysplasia characterized by insufficient osteocla...
Lack of or dysfunction in osteoclasts result in osteopetrosis, a group of rare but often severe, gen...
Bone biopsies were performed before and 7 weeks after transplantation of HLA-compatible bone marrow ...